Journal of Immunology Research

Research Article

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis

Table 1

Characteristics of all studies included in the meta-analysis.


Author, year	Age group	Study groups	Estimated GFR (ml/min per 1.73 m²)		Gender M/F	Age ( or range)	suPAR levels (pg/ml)

Bock et al., 2013 [18]	Children	Control	N/A	29	N/A	N/A
		pFSGS		20	12 : 8
		MCD		5	N/A	N/A
		IgAN		3	N/A	N/A

Huang et al., 2013 [15]	Adult + children	Control	Graphs only	56	33 : 23	21-47
		pFSGS		74	50 : 24	13-84
		MCD		14	7 : 7	17-71
		MN		29	18 : 11	33-79

Franco Palacios et al., 2013 [19]	Adult	Control	Inverse correlation with eGFR (, )	10	4 : 6
Franco Palacios et al., 2013 [19]	Adult	pFSGS		28	N/A

Wada et al., 2014 [20]	Adult	Control	Inverse correlation with eGFR (, )	17	9 : 8
		pFSGS		38	26 : 12
		MCD		11	6 : 5
		MN		9	4 : 5
		IgAN		11	5 : 6

Sinha et al., 2014 [14]	Children	Control		83	42 : 41
		pFSGS-A	^a	46	83:37^a	^a
		pFSGS-N	Inverse correlation with eGFR ()	28
		pFSGS-R		52	a
		MCD-A		54	85:32^b	^b
		MCD-N		17			2947 ± 875
		MCD-R		71			3204 ± 1176

Li et al., 2014 [13]	Adult	Control		96	73 : 23
		pFSGS		109	83 : 26
		MCD	No correlation with eGFR	20	17 : 3
		MN		22	19 : 3

Meijers et al., 2014 [21]	Adult	pFSGS-A	62.5 (36.8–98.7)	44	31 : 13
Meijers et al., 2014 [21]	Adult	pFSGS-R	57.7 (47.2–92.4)	10	5 : 5

Segarra et al., 2014 [22]	Adult	pFSGS	Inverse correlation with eGFR (: –0.467, )	20	11 : 9
		MCD		16	6 : 10
		MN		24	16 : 8

Spinale et al., 2015 [23]	Adult + children	pFSGS		95	64 : 31
		MCD		62	36 : 26
		MN		52	32 : 20
		IgAN		32	19 : 13

Fujimoto et al., 2015 [24]	Adult	Control		20	15 : 5
		pFSGS		8	4 : 4
		MCD		12	7 : 5
		MN		15	11 : 4

Jin et al., 2015 [25]	Adult	Control		69	39 : 30
		pFSGS		86	48 : 38
		MCD		65	34;31
		MN		85	50 : 35

Chen et al., 2016 [26]	Adult	pFSGS		18	14 : 4
Chen et al., 2016 [26]	Adult	MCD		22	19 : 3

Sołtysiak et al., 2016 [27]	Children	Control	Inverse correlation with eGFR	16	N/A	^c
		pFSGS	(: –0.643, not given)	9	N/A
		MCD		22	N/A

^aData for all patients with FSGS; ^bdata for all patients with MCD; ^cdata for all participants in this study. Abbreviation used: SUPAR: soluble urokinase-type plasminogen activator receptor; pFSGS: primary focal segmental glomerulosclerosis; pFSGS-A: active primary FSGS in remission; pFSGS-R: pFSGS in remission; MCD: minimal change disease; MN: membranous nephropathy; IgAN: immunoglobulin A nephropathy; N: number; N/A: not available; SD: standard deviation.